China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for CMS-D017, a self-developed oral selective inhibitor of complement factor B.

The upcoming Phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017, which is intended for the treatment of complement-mediated kidney diseases such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis and C3 glomerulopathy.

CMS-D017 already received NMPA clearance on Jan, 30 2026 for clinical testing in paroxysmal nocturnal hemoglobinuria, and the company plans to explore additional indications including age-related macular degeneration and myasthenia gravis.

According to the company, a future marketing approval for CMS-D017 would complement its nephrology portfolio, which includes the marketed phosphate binder Velphoro and the investigational anemia therapy Desidustat Tablets.

China Medical System said it is preparing to start the clinical study and will update shareholders on further developments, while advising investors to act cautiously when trading its securities.